Free Trial

Matthew Stanton Analyst Performance

Analyst at Jefferies Financial Group

Matthew Stanton is a stock analyst at Jefferies Financial Group in the medical sector, covering 2 publicly traded companies. Over the past year, Matthew Stanton has issued 5 stock ratings, including buy and hold recommendations. While full access to Matthew Stanton's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matthew Stanton's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
60.00% 3 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy60.0%3 ratings
Hold40.0%2 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Matthew Stanton at Jefferies Financial Group, the majority (60.0%) have been Buy recommendations, followed by 40.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
2 companies

Matthew Stanton, an analyst at Jefferies Financial Group, currently covers 2 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Matthew Stanton of Jefferies Financial Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MEDICAL INFO SYS
1 company
50.0%
MED - BIOMED/GENE
1 company
50.0%

Matthew Stanton's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Azenta, Inc. stock logo
AZTA
Azenta
2/4/2026Lower Price Target$28.13$40.00Buy
Azenta, Inc. stock logo
AZTA
Azenta
10/30/2025Upgrade$29.79$38.00Buy
Azenta, Inc. stock logo
AZTA
Azenta
10/30/2025Set Price Target$29.79$38.00Buy
Repligen Corporation stock logo
RGEN
Repligen
10/28/2025Set Price Target$153.68$160.00Hold
Repligen Corporation stock logo
RGEN
Repligen
9/12/2025Lower Price Target$119.51$135.00Hold